IsomAb secures £7.5M for treatment of diabetic peripheral arterial disease

IsomAb founders have developed an antibody that unlocks new blood vessel formation in diabetes, preventing ulcers and irreversible tissue damage.
IsomAb secures £7.5M for treatment of diabetic peripheral arterial disease

Today IsomAb — a University of Nottingham spin-out pioneering a new treatment for people with diabetes at risk of amputation — has raised £7.5 million in funding. 

The company focuses on treating peripheral arterial disease (PAD). In this relatively common condition, the arteries in the legs and feet become blocked by fatty deposits, resulting in a lack of blood flow.

In many cases, the body successfully compensates by developing new blood vessels in a process known as angiogenesis. However, this process of compensation does not seem to occur in diabetics, and the lack of circulation often causes ulcers and irreversible tissue damage.

Research by IsomAb's founders, Professor David Bates and Professor Steve Harper, suggests that this is because a protein called VEGF-A165b blocks the angiogenesis process in diabetics. 

The IsomAb team have developed an antibody that inhibits the effects of the protein and allows new blood vessels to be created.

Founded in 2022, IsomAb is the second spin-out by the pair. Their previous venture, Exonate Ltd, focuses on treating diabetic macular oedema and has successfully completed its first clinical trial.

The funding round is led by Broadview Ventures and backed by MEIF Proof of Concept & Early Stage Fund, managed by Mercia Ventures and part of the Midlands Engine Investment Fund (MEIF), Mercia's EIS funds and existing investor SCVC.

Jackie Turnbull, CEO of IsomAb, commented: 

"IsomAb's lead program, targeting VEGF-A165b, aims to treat peripheral arterial disease in a large proportion of patients with concomitant metabolic syndrome and Type II diabetes. 

We are delighted to have attracted a group of high-quality investors to support the early development of our novel program toward CTA filing to enter the clinic."

Benjamin Kreitman, Principal at Broadview Ventures, said: 

"Peripheral artery disease remains a significant unmet medical need worldwide, and the development of novel treatments to alleviate ischemia could improve clinical care for millions of patients. 

As Broadview's investment strategy is focused on improving human health in cardiovascular disease and stroke, we are delighted to accelerate this highly innovative approach."

The funding will enable IsomAb to carry out further studies in preparation for the start of clinical trials.

Lead image: IsomAb. Photo: uncredited.

Follow the developments in the technology world. What would you like us to deliver to you?
Your subscription registration has been successfully created.